Company Analysis

AN2 Therapeutics, Inc. (ANTX)

Nasdaq: ANTX · Pharmaceutical Preparations · Menlo Park, CA · filing with the SEC since 2021
Grade5.8
◀ Past 5.6● Present 6.6▶ Future 5.2
7 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to AN2 Therapeutics, Inc.’s names, not what it holds today.

Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
2
2 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
AN2 Therapeutics, Inc. its own name
US, as the owner printed on each patent
0 granted
2 published
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 16, 20252025/0319108COMBINATIONSPharmaceuticalsAN2 Therapeutics, Inc.
Jan 2, 20252025/0000883TREATING NEUROINFLAMMATORY CONDITIONSPharmaceuticalsAN2 Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ANTX · research, not advice